Melanie M Ashton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/876741/publications.pdf

Version: 2024-02-01

23 papers 531 citations

933447 10 h-index 23 g-index

24 all docs

24 docs citations

times ranked

24

1086 citing authors

#	Article	IF	CITATIONS
1	Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression. Acta Neuropsychiatrica, 2022, 34, 220-227.	2.1	7
2	Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials. Australian and New Zealand Journal of Psychiatry, 2021, 55, 784-798.	2.3	16
3	Systematic review and meta-analysis of the role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders. Journal of Affective Disorders, 2021, 279, 711-721.	4.1	9
4	A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder. Canadian Journal of Psychiatry, 2021, 66, 262-273.	1.9	11
5	Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d'essais randomisés contrÃ1és. Canadian lournal of Psychiatry, 2021, 66, 849-862.	1.9	19
6	The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial. Frontiers in Psychiatry, 2021, 12, 626486.	2.6	3
7	Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial. Journal of Psychiatric Research, 2021, 142, 376-383.	3.1	1
8	Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: Péricarpe d'appoint Garcinia mangostana Linn (mangoustan) pour la schizophrénie : un essai d'efficacité de 24 semaines, à double insu, randomisé et contrÃ1é par placebo. Canadian Journal of Psychiatry, 2021, 66, 354-366.	1.9	3
9	Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial. Revista Brasileira De Psiquiatria, 2020, 42, 14-21.	1.7	7
10	Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive <i>N</i> -acetylcysteine and mitochondrial agents in adults with bipolar disorder: A sub-study of a randomised placebo-controlled trial. Australian and New Zealand Journal of Psychiatry, 2020, 54, 159-172.	2.3	11
11	Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled Trial. Canadian Journal of Psychiatry, 2020, 65, 306-318.	1.9	9
12	Prebiotics, probiotics, fermented foods and cognitive outcomes: A meta-analysis of randomized controlled trials. Neuroscience and Biobehavioral Reviews, 2020, 118, 472-484.	6.1	50
13	Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2019, 17, 297-307.	2.0	5
14	Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: protocol for a systematic review. BMJ Open, 2019, 9, e025640.	1.9	5
15	Role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders: a protocol for a systematic review and meta-analysis. BMJ Open, 2019, 9, e025145.	1.9	5
16	The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia. Frontiers in Psychiatry, 2019, 10, 115.	2.6	16
17	Efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial. Revista Brasileira De Psiquiatria, 2019, 41, 245-253.	1.7	8
18	Mitochondrial Agents for Bipolar Disorder. International Journal of Neuropsychopharmacology, 2018, 21, 550-569.	2.1	31

#	Article	IF	CITATIONS
19	Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial. Australian and New Zealand Journal of Psychiatry, 2017, 51, 829-840.	2.3	75
20	Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry, 2017, 16, 236-244.	10.4	160
21	Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study. Advances in Integrative Medicine, 2017, 4, 109-114.	0.9	3
22	Beyond the therapeutic shackles of the monoamines: New mechanisms in bipolar disorder biology. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 72, 73-86.	4.8	31
23	Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial. Clinical Psychopharmacology and Neuroscience, 2014, 12, 180-188.	2.0	46